BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tocris Bioscience Signs Deal To Supply Pfizer Inc. (PFE) Research Compounds


3/15/2010 1:31:55 PM

15th March 2010: Tocris Bioscience (Bristol, UK) announced today that it has entered into an agreement with Pfizer which will result in a wide range of Pfizer compounds being made available to the global research community.

For the first time, scientists involved in preclinical research will now be able to purchase authentic, fully-licensed, non-formulated, sunitinib, varenicline and other Pfizer compounds as off-the shelf products for use in their preclinical research studies. In addition, a significant number of Pfizer's ‘literature compounds’ - biologically active small molecules that have not progressed from development to clinical use - will also be offered for sale.

Typically supplied in 10 and 50 milligram pack sizes ideally suited for preclinical laboratory research applications, the availability of these products through Tocris will benefit scientists working in a diverse range of fields, including neuroscience, cancer and metabolic disease.

"We are pleased to be working with Tocris" noted Richard Connell, VP of External Research Solutions CoE at Pfizer. "Tocris has an excellent track record of respecting Pfizer’s intellectual property while making a range of important compounds available to the research community. We appreciate the innovative and creative ways they listen to and serve life science researchers in academia and industry".

Laurence Ede, Tocris' Managing Director, added "Pfizer's portfolio of compounds is world class and I'm very excited that Tocris has the opportunity to provide preclinical researchers with access to these materials. These important new additions perfectly complement Tocris' range of high purity compounds, which are used by scientists worldwide in the furtherance of biomedical research. We are delighted to enter into this agreement with Pfizer and look forward to working in close partnership together going forward."

About Tocris

For over a quarter of a century Tocris Bioscience has been established as a leading supplier of innovative high performance life science research reagents, with customers throughout the world's pharmaceutical companies, universities and research institutes. Our range of over 3,000 life science reagents consists of small molecules, peptides and antibodies, and represents a unique collection of novel and exclusive research tools, including GPCR ligands, neurotransmitters, ion channel modulators, signaling inhibitors and much more. With our industry-leading quality, next day delivery and first-class technical support, Tocris is the first place to look for all your research needs. To learn more, please visit our website at www.tocris.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES